Preclinical Data Presentations At Keystone Symposia Highlight Broad...

Peregrine Pharmaceuticals, Inc. today announced that preclinical data presented at two Keystone Symposia support the immune-stimulatory mechanism of action and therapeutic potential of the company's phosphatidylserine -targeting antibodies in both oncology and antiviral therapeutic areas.

http://ift.tt/1cG2z3H